

## Goals/ Definition

To describe a detailed plan to scale-up manufacturing to provide larger amounts (kilo scale) of clinical trial materials (drug substance and drug product) that will be required for Phase 2 clinical trials.

CMC development plan updated.

CRITERIA	SAMPLE CONTENT REQUIREMENT	GUIDELINES FOR LEVEL OF DETAIL NEEDED AT EACH GATE
<ul style="list-style-type: none"> <li>▪ List of activities that will be conducted, that lead to achieving the “DS/DP Characterized at Kilo-Scale” milestone at EP1 stage gate</li> </ul>	<ul style="list-style-type: none"> <li>• Complete initial drug product characterization</li> <li>• Define cGMP manufacturing process</li> <li>• Complete GMP manufacturing for Ph 1</li> <li>• Finalize DS characterization &amp; analytical method development</li> <li>• Manufacture DS at kilo-scale</li> <li>• Complete DP characterization</li> <li>• Complete DP package characterization</li> <li>• Manufacture DP to support the Phase 2 clinical trial</li> <li>• Manufacturing process optimization</li> <li>• GMP manufacturing for Ph 3</li> <li>• Readiness for Tech Transfer</li> <li>• Technology transfer and validation of raw material, drug substance, and drug product analytical and functional release testing</li> <li>• Technology transfer and validation of drug substance &amp; drug product manufacturing and packaging processes</li> <li>• Qualification of commercial-scale facilities</li> <li>• Commercial launch strategy</li> <li>• QA/compliance activities</li> <li>• Ongoing CMC Support to ensure uninterrupted supply of high quality DP in all markets</li> </ul>	<ul style="list-style-type: none"> <li>▪ A detailed plan to achieve the EP1 CMC milestones is expected</li> <li>▪ Additionally, the Plan should identify potential development risks to PQ, and risk mitigation strategies related to development timeline, costs and resource allocation</li> </ul>